Recent Finacing
Recent Raise
Sydnexis is a clinical-stage pharmaceutical company developing SYD-101, a low-dose (0.01% and 0.03%) atropine eye-drop formulation for pediatric progressive myopia, currently in a pivotal Phase 3 STAAR study.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Sydnexis.
